Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-12-05 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of discernible information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report.
2023-12-05 English
4
Director's Dealing
2023-11-29 English
3
Director's Dealing
2023-11-29 English
4
Director's Dealing
2023-11-21 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by Amylyx Pharmaceuticals, Inc. It announces the issuance of a press release with financial results for the fiscal quarter ended September 30, 2023. The document itself does not contain the financial results but rather furnishes the press release as an exhibit. The text explicitly states that the information is not "filed" for certain regulatory purposes and is a current report. The length is 3509 characters, which is relatively short and consistent with an announcement rather than a full financial report. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to earnings releases or financial results announcements. Since the document is a Form 8-K announcing the earnings release and includes the press release as an exhibit, it is best classified as an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-11-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.